Di Donato Violante, Giannini Andrea, D'Oria Ottavia, Schiavi Michele Carlo, Di Pinto Anna, Fischetti Margherita, Lecce Francesca, Perniola Giorgia, Battaglia Francesco, Berloco Pasquale, Muzii Ludovico, Benedetti Panici Pierluigi
Department of Maternal and Child Health and Urological Sciences, "Sapienza" University of Rome, Umberto I Hospital, Rome, Italy.
Department Obstetrics and Gynecological Hospital Santa Maria Goretti of Latina, "Sapienza" University of Rome, Rome, Italy.
Ann Surg Oncol. 2021 Jan;28(1):222-230. doi: 10.1245/s10434-020-08989-3. Epub 2020 Aug 10.
The purpose of this study was to evaluate the feasibility and safety in terms of prognostic significance and perioperative morbidity and mortality of cytoreduction in patients affected by advance ovarian cancer and hepato-biliary metastasis.
Patients with a least one hepatobiliary metastasis who have undergone surgical treatment with curative intent of were considered for the study. Perioperative complications were evaluated and graded with Accordion severity Classification. Five-year PFS and OS were estimated using the Kaplan-Meier curve.
Sixty-seven (20.9%) patients had at least one metastasis to the liver, biliary tract, or porta hepatis. Forty-four (65.7%) and 23 (34.3%) patients underwent respectively high and intermediate complexity surgery according. Complete cytoreduction was achieved in 48 (71.6%) patients with hepato-biliary disease. In two patients (2.9%) severe complications related to hepatobiliary surgery were reported. The median PFS for the patients with hepato-biliary involvement (RT = 0 vs. RT > 0) was 19 months [95% confidence interval (CI) 16.2-21.8] and 8 months (95% CI 6.1-9.9). The median OS for the patients with hepato-biliary involvement (RT = 0 vs. RT > 0) 45 months (95% CI 21.2-68.8 months) and 23 months (95% CI 13.9-32.03).
Hepatobiliary involvement is often associated with high tumor load and could require high complex multivisceral surgery. In selected patients complete cytoreduction could offer survival benefits. Morbidity related to hepatobiliary procedures is acceptable. Careful evaluation of patients and multidisciplinary approach in referral centers is mandatory.
本研究旨在评估晚期卵巢癌合并肝胆转移患者进行肿瘤细胞减灭术的可行性和安全性,包括其对预后的意义以及围手术期的发病率和死亡率。
本研究纳入了至少有一处肝胆转移且接受了根治性手术治疗的患者。围手术期并发症采用手风琴严重程度分类法进行评估和分级。使用Kaplan-Meier曲线估计五年无进展生存期(PFS)和总生存期(OS)。
67例(20.9%)患者至少有一处肝脏、胆道或肝门转移。44例(65.7%)和23例(34.3%)患者分别接受了高复杂性和中等复杂性手术。48例(71.6%)患有肝胆疾病的患者实现了完全肿瘤细胞减灭。报告了2例(2.9%)与肝胆手术相关的严重并发症。肝胆受累患者(放疗=0 vs.放疗>0)的中位PFS分别为19个月[95%置信区间(CI)16.2-21.8]和8个月(95%CI 6.1-9.9)。肝胆受累患者(放疗=0 vs.放疗>0)的中位OS分别为45个月(95%CI 21.2-68.8个月)和23个月(95%CI 13.9-32.03)。
肝胆受累常与高肿瘤负荷相关,可能需要进行高复杂性的多脏器手术。在选定的患者中,完全肿瘤细胞减灭术可带来生存益处。与肝胆手术相关的发病率是可接受的。在转诊中心对患者进行仔细评估并采用多学科方法是必不可少的。